Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes

J Leukoc Biol. 2004 Oct;76(4):812-9. doi: 10.1189/jlb.0304182. Epub 2004 Jul 26.

Abstract

Plasminogen activator inhibitor-2 (PAI-2) as a potential eosinophil protein was inferred from our gene microarray study of mouse eosinophilopoiesis. Here, we detect 47 kDa intracellular and approximately 60 kDa secretory forms of PAI-2 in purified human eosinophil extracts. PAI-2 is present at variable concentrations in eosinophil lysates, ranging from 30 to 444 ng/10(6) cells, with a mean of 182 ng/10(6) cells from 10 normal donors, which is the highest per-cell concentration among all leukocyte subtypes evaluated. Enzymatic assay confirmed that eosinophil-derived PAI-2 is biologically active and inhibits activation of its preferred substrate, urokinase. Immunohistochemical and immunogold staining demonstrated PAI-2 localization in eosinophil-specific granules. Immunoreactive PAI-2 was detected in extracellular deposits in and around the eosinophil-enriched granuloma tissue encapsulating the parasitic egg in livers of wild-type mice infected with the helminthic parasite Schistosoma mansoni. Among the possibilities, we consider a role for eosinophil-derived PAI-2 in inflammation and remodeling associated with parasitic infection as well as allergic airways disease, respiratory virus infection, and host responses to tumors and metastasis in vivo.

MeSH terms

  • Animals
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Eosinophils / immunology*
  • Eosinophils / parasitology
  • Granuloma / parasitology
  • Humans
  • Interleukin-5 / genetics
  • Interleukin-5 / physiology
  • Liver / parasitology
  • Mice
  • Ovum / parasitology
  • Plasminogen Activator Inhibitor 2 / metabolism*
  • Schistosoma mansoni / pathogenicity*
  • Urokinase-Type Plasminogen Activator / metabolism*

Substances

  • Interleukin-5
  • Plasminogen Activator Inhibitor 2
  • Urokinase-Type Plasminogen Activator